"SAFETY ONLY" DEVICE EVALUATION INCONSISTENT WITH COST- CONTAINMENT
This article was originally published in The Gray Sheet
Executive Summary
"SAFETY ONLY" DEVICE EVALUATION INCONSISTENT WITH COST- CONTAINMENT trends in the medical care industry, FDA says in a recent background document responding to calls for the Center for Devices and Radiological Health to regulate only the safety, and not the effectiveness, of medical devices. "In an era of increasing emphasis on cost-containment," FDA contends, a "safety only" device evaluation system "would waste money by subjecting patients to ineffective treatments before the 'medical marketplace' weeded them out." FDA released the backgrounder in response to an Aug. 12 report on the ABC News television program "20/20" that was highly critical of CDRH's approval policies.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.